IPO Details

About Company

Anlon Healthcare Limited, incorporated in 2013, is a pharmaceutical chemical manufacturer specializing in pharma intermediates and active pharmaceutical ingredients (APIs). The company produces high-purity intermediates (used in API production) and APIs (used in medicines, nutraceuticals, personal care, and animal health). Its products comply with major pharmacopeia standards including IP, BP, EP, JP, and USP. In addition to its standard portfolio, Anlon also offers custom manufacturing for complex chemicals, meeting stringent purity requirements tailored to customer needs. The company has received Drug Master File (DMF) approvals from international authorities like ANVISA, NMPA, and PMDA, and has filed 21 DMFs globally, with more in the pipeline for products like Ketoprofen and Dexketoprofen Trometamol. Its product portfolio covers 65 commercialized APIs, 28 in the pilot stage, and 49 in laboratory testing. Major offerings include Pharma Intermediates (Cyanoethylbenzoic acid, Ketonitrile, Methyldesloratadine) and APIs that are used across formulations such as tablets, capsules, ointments, syrups, nutraceuticals, veterinary medicines, and personal care products. The company employs 105 staff and 8 contract workers (as of Jan 31, 2025) and maintains rigorous quality assurance, in-house testing, and process improvement systems across four laboratories. With a 34-member technical team (24 science graduates), it ensures compliance with global standards.